Insider · CIK 0001952679
Daniel George Wildman
Files at URGN (UroGen Pharma Ltd.). First filing -, latest -.
Daniel George Wildman files SEC Form 4 as director at URGN (UroGen Pharma Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Daniel George Wildman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | MOption exercise ordinary shares | +2,000 | - | - | 2,000 | Dec 1, 2025 |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitderivative | -2,000 | $0.00 | $0 | 6,000 | Dec 1, 2025 |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | AGrant or award Stock Option (right ot buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Aug 27, 2025 |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | AGrant or award Restricted Stock Unitderivative | +8,000 | $0.00 | $0 | 8,000 | Aug 27, 2025 |
Questions about Daniel George Wildman
Answered from the filings on this page, as of the latest one.
Is Daniel George Wildman buying or selling?
Daniel George Wildman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Daniel George Wildman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Daniel George Wildman has 0.
Where does Daniel George Wildman file Form 4?
Daniel George Wildman has filed Form 4 at URGN (UroGen Pharma Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.